Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biologics in the treatment of skin and rheumatologic diseases.

Literature DB >> 32112793

Biologics in the treatment of skin and rheumatologic diseases.

J Michelle Kahlenberg¹, Allison C Billi², Kilian Eyerich³, Johann E Gudjonsson⁴.

Abstract

Entities: Chemical

Keywords: Inflammation; autoimmune disease; autoinflammatory; biologics

Mesh：

Substances：

Year: 2020 PMID： 32112793 PMCID： PMC8842991 DOI： 10.1016/j.jaci.2020.02.017

Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793

Keyword Cloud
References

× No keyword cloud information.

10 in total

Review 1. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

Authors: Niels Vande Casteele; Hans Herfarth; Jeffry Katz; Yngve Falck-Ytter; Siddharth Singh
Journal: Gastroenterology Date: 2017-07-31 Impact factor: 22.682

2. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.

Authors: Henri Thiebault; Pauline Boyard-Lasselin; Caroline Guignant; Nicolas Guillaume; Adrien Wacrenier; Charles Sabbagh; Lionel Rebibo; Franck Brazier; Jonathan Meynier; Eric Nguyen-Khac; Jean-Louis Dupas; Vincent Goëb; Mathurin Fumery
Journal: Eur J Gastroenterol Hepatol Date: 2016-08 Impact factor: 2.566

3. Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Authors: Frederick W Jacobsen; Riki Stevenson; Cynthia Li; Hossein Salimi-Moosavi; Ling Liu; Jie Wen; Quanzhou Luo; Kristine Daris; Lynette Buck; Sterling Miller; Shu-Yin Ho; Wei Wang; Qing Chen; Kenneth Walker; Jette Wypych; Linda Narhi; Kannan Gunasekaran
Journal: J Biol Chem Date: 2016-12-19 Impact factor: 5.157

4. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Authors: Éric Toussirot; Éric Houvenagel; Vincent Goëb; Damien Fouache; Antoine Martin; Philippe Le Dantec; Emmanuelle Dernis; Daniel Wendling; Thiphaine Ansemant; Jean-Marie Berthelot; Brigitte Bader-Meunier; Bernadette Kantelip
Journal: Joint Bone Spine Date: 2011-11-15 Impact factor: 4.929

5. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

Authors: K Papp; J Crowley; J-P Ortonne; J Leu; M Okun; S R Gupta; Y Gu; R G Langley
Journal: Br J Dermatol Date: 2011-02 Impact factor: 9.302

Biologics in the treatment of skin and rheumatologic diseases.

Review 1. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

2. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.

3. Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

4. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

5. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

Review 6. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

7. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.

8. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Review 9. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Review 10. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.